Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-tocopheroloxyacetic acid - Veana Therapeutics

Next Previous
Drug Profile

Alpha-tocopheroloxyacetic acid - Veana Therapeutics

Alternative Names: 12-trimethyltridecyl) chroman-6-yloxy) acetic Acid; 261929-52-6; alpha-TEA; Oral Vimo-001; Oral Vimo-002; Oral Vimo-003; Oral Vimo-004; Oral Vimo-005; Vimo 001; Vimo 002; Vimo 003; Vimo 004; Vimo 005; Vimo-V001; VT-101; α-TEA - Veana Therapeutics

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Veana Therapeutics
  • Developer Providence Health & Services; Veana Therapeutics
  • Class Antineoplastics; Cancer vaccines; Small molecules
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HER2 positive breast cancer
  • Preclinical Cancer; Prostate cancer; Triple negative breast cancer
  • Discontinued Carcinoma; Lymphoma; Sarcoma

Most Recent Events

  • 06 Feb 2025 Alpha-tocopheroloxyacetic acid is still in phase-I development in HER2-positive-breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 06 Feb 2025 Preclinical trials in Triple-negative-breast-cancer in USA (PO) (Veana Therapeutics pipeline, February 2025)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top